Ikena Oncology Inc. (IKNA) Adds Dr. Maria Koehler to Board
- FANGS and BATS sell-off spooks world stocks
- Commodity gains restrain dollar ahead of inflation data
- FDA Authorizes Pfizer (PFE) - BioNTech (BNTX) Vaccine for Emergency Use in Adolescents
- Wynn Interactive to Merge with SPAC Austerlitz Acquisition Corporation I (AUS)
- Tesla (TSLA) Halts Plans to Buy Land in Shanghai Amid Increased Tensions with China: Report
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Ikena Oncology, Inc. (NASDAQ: IKNA) today announced the appointment of Maria Koehler, M.D., Ph.D. to its Board of Directors. Dr. Koehler is a board-certified hematologist and oncologist with more than 20 years of pharmaceutical and biotech oncology experience in clinical development, including senior roles at Pfizer where she led the development of Ibrance® (palbociclib) and contributed to the strategic direction of the oncology portfolio.
“We are extremely pleased to welcome Maria to our Board of Directors at this important next stage of Ikena’s evolution,” said Mark Manfredi, President & Chief Executive Officer of Ikena. “Maria is a highly accomplished biopharmaceutical veteran. During her distinguished career, she has led the development of numerous oncology drugs from early- to late-stage clinical investigation, through to commercialization. Her leadership and strategic expertise will be invaluable as we advance IK-930, our lead targeted oncology candidate, into clinical development, followed thereafter by our other pipeline programs targeting cancers with high unmet need.”
“It is a privilege to join Ikena’s Board of Directors during such an exciting period of growth following the Company’s recent IPO, and as Ikena advances IK-930 towards clinical development during the second half of 2021,” said Dr. Koehler. “I look forward to working alongside Ikena’s current Board members and executive management to advance Ikena’s innovative drug candidates through clinical development and toward commercialization where they can truly benefit patients.”
Dr. Koehler brings deep experience in both early drug development and bringing new drugs to global markets, having developed strategies for product candidates at all stages of development. Dr. Koehler currently serves as the Chief Medical Officer at Repare Therapeutics (RPTX), where she leads clinical strategy and oversees all operations. Dr. Koehler joined Repare from Bicycle Therapeutics (BCYC) where she was Chief Medical Officer. Prior to Bicycle, she was Vice President of Strategy, Innovation and Collaborations for the Oncology Business Unit at Pfizer. Prior to Pfizer, she served in leadership roles at GlaxoSmithKline and at AstraZeneca. She is board certified in hematology and oncology. She began her career as a practicing physician and served as the clinical director of Bone Marrow Transplantation at University Hospital in Pittsburgh as well as the director of the Bone Marrow Transplant Program and associate professor at St. Christopher’s Hospital in Philadelphia. Dr. Koehler received her M.D. and Ph.D. from the Silesian Medical School in Poland and has co-authored over 150 publications, book chapters, and patents.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Molina Healthcare (MOH) Reports Election of Dr. Stephen Lockhart to Board
- Ritchie Bros. Auctioneers (RBA) Reports In-Line Q1 EPS, Revenues Beat
- Guild Holdings Company (GHLD) Reports Acquisition of Residential Mortgage Services Holdings
Create E-mail Alert Related CategoriesBoard Changes, Corporate News, Management Comments
Related EntitiesTwitter, S1, IPO
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!